comparemela.com

Sean Gjos News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SaNOtize Research & Development Corp : SaNOtize Announces $24 Million in Series B Funding to Advance Its Nitric Oxide-Based Therapeutics, Including Nasal Spray for the Treatment and Prevention of COVID-19

Co-led by Horizons Ventures and OurCrowd, new funding enables SaNOtize to invest in its ongoing Phase 3 clinical trial for COVID-19 prevention and enhance clinical development of its other nitric

United statesHong kongBritish columbiaSri lankaChris millerKostenloser wertpapierhandelFrances kangSean gjosJon medvedGilly regevSanotize coLancet regional health southeast asiaCentral drugs standard control organizationSanotize research development corpEuropean unionBusiness development

SaNOtize Research & Development Corp : Newly Published Phase 3 Study in People with COVID-19 Shows SaNOtize Nitric Oxide Nasal Spray Reduced Viral Load by 99% within Two Days

Phase 3 trial demonstrated a reduction in SARS-CoV-2 viral load in high-risk COVID-19 patients by 94% and 99% within 24 and 48 hours of treatment, respectively Median time to a negative PCR

Hong kongUnited kingdomBritish columbiaChris millerKostenloser wertpapierhandelSean gjosGilly regevSanotize coThelancet regional health southeast asiaSanotize research development corpEuropean unionIndia central drugs standard control organizationGlenmark pharmaceuticals limitedBusiness developmentResearch development corpProgression scale

Clinical Study Suggests SaNOtize Nitric Oxide Nasal Spray Is Effective at Preventing COVID-19 after High-Risk Exposure

VANCOUVER, British Columbia (BUSINESS WIRE) May 11, 2022

Krung thep mahanakhonUnited kingdomBritish columbiaNakhon nayokJarinratn sirirattawanSean gjosProfessor srinakharinwirot universitySanotize research development corpDevelopment sanotizeSanotize researchSrinakharinwirot universityBusiness developmentAssistant professorBusiness wire

vimarsana © 2020. All Rights Reserved.